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Abstract
Background: Despite aggressive therapy, advanced stage neuroblastoma patients have poor
survival rates. Although angiogenesis correlates with advanced tumour stage and plays an important
role in determining the tumour response to treatment in general, clinical data are still insufficient,
and more clinical evaluations are needed to draw conclusions. The aim of this study was to evaluate
vascular endothelial growth factor (VEGF) expression in patients with neuroblastoma, determine
whether it correlates with other prognostic factors and/or therapeutic response, and to assess
should VEGF be considered in a routine diagnostic workup.
Materials and methods: VEGF expression was determined by immunohistochemistry using anti-
VEGF antibody in paraffin embedded primary tumour tissue from 56 neuroblastoma patients.
Semiquantitative expression of VEGF was estimated and compared with gender, age, histology,
disease stage, therapy, and survival. Statistical analyses, including multivariate analysis, were
performed.
Results: VEGF expression correlated with disease stage and survival in neuroblastoma patients.
Combination of VEGF expression and disease stage as a single prognostic value for survival (P-value
= 0.0034; odds ratio (OR) (95%CI) = 26.17 (2.97-230.27) exhibited greater correlation with
survival than individually. Hematopoietic stem cell transplantation significantly improved survival of
the advanced stage patients with high VEGF expression.
Conclusion: VEGF expression should be considered in a routine diagnostic workup of children
with neuroblastoma, especially in those more than 18 months old and with advanced disease stage.
High VEGF expression at the time of disease diagnosis is a bad risk prognostic factor, and can be
used to characterize subsets of patients with an unfavourable outcome.
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Neuroblastoma (NB), a paediatric solid tumour of neural
crest origin, is the most frequent extracranial solid malig-
nancy in children. Despite intensive multimodal therapy,
the prognosis of patients older than 1 year with advanced
disease remains poor, with long term survival less than
40%. A consensus was reached in determining the neu-
roblastoma risk stratification schema considering age,
stage and N-myc status [1]. In general, angiogenesis plays
an important role in the progression and metastasis of
malignant tumours [2]. In neuroblastoma, tumour vascu-
larity is correlated with an aggressive phenotype [3,4].
Pro-angiogenic factors are differentially expressed in high-
risk neuroblastoma [5,6]. Vascular endothelial growth
factor (VEGF) is a specific endothelial cell mitogen that
stimulates angiogenesis and plays a crucial role in tumour
growth [7]. Overexpression of VEGF has been demon-
strated in neuroblastoma, nephroblastoma, as well as in
other cancers, such as colon, breast, brain, lung, malig-
nant pleural mesothelioma, esophageal and gastric carci-
nomas [8-10]. In adult solid tumours VEGF expression
has been successfully evaluated by immunohistochemis-
try, and has been reported to be an independent prognos-
tic factor [11-15]. Recent studies have validated inhibition
of VEGF as an effective antiangiogenic therapy in some of
these cancers [16-18]. Although several preliminary stud-
ies have demonstrated that expression of angiogenic
growth factors, including VEGF, correlate with a high-risk
phenotype in neuroblastoma, clinical data are still insuf-
ficient to draw conclusions [5,9,19-21]. Therefore, further
clinical studies, are needed to evaluate the possible signif-
icance of these factors for use in a routine clinical practice.
Preclinical studies also suggest that antiangiogenic strate-
gies may be effective in the treatment of neuroblastoma
[22,23]. Whether inhibition of angiogenesis is a realistic
approach for preventing dissemination of neuroblastoma,
remains to be determined. In addition, phase I clinical tri-
als (COG study) using the human anti-VEGF antibody,
bevacizumab, in pediatric patients with refractory solid
tumours reported promising results [24].
The aim of this study was to evaluate VEGF expression in
patients with neuroblastoma and determine whether it
correlates with other prognostic factors and/or therapeutic
response. Also, we tried to assess should VEGF be consid-
ered in a routine diagnostic workup of children with neu-
roblastoma. Maybe these results could help in the
planning further follow-up strategies and antiangiogenic
therapy trials.
Materials and methods
Patients and tumour samples
Neuroblastoma tissue samples (n = 56) included in this
study were retrieved from the archives of the Institute of
Pathology Medical School University of Zagreb, Croatia.
They were obtained from patients treated at the Children's
Clinical Hospital Zagreb between 1995 and 2008 at the
beginning of disease (first biopsy). Clinical staging was
classified according to The International Neuroblastoma
Staging System (INSS) [1,25]. Histopathological grading
was classified according to Shimada System and Shimada
Age-based Pathologic Classification [26,27]. All the histo-
logical samples underwent a revaluation and new grading
(SS). Patients with stage 1, 2 and stage 4s disease (19
patients) were treated with surgery alone, or surgery and
moderate-dose chemotherapy. Patients with stage 3 and 4
(37 patients) were treated with surgery combined with
intensive, multiagent chemotherapy either with or with-
out radiotherapy and/or metaiodobenzylguanidine
(MIBG) therapy. Fourteen patients with advanced disease,
and 3 patients with localized disease with N-myc amplifi-
cation tumour received megatherapy (myeloablative
chemotherapy) followed by autologous or allogeneic
hematopoietic stem cell transplantation. As hematopoi-
etic stem cell transplantation for our high-risk patients
was started in 1999, there were 2 groups of high risk
patients, either treated with or without stem cell trans-
plantation (Table 1).
Immunohistochemistry
Immunohistochemical analysis was performed on forma-
lin-fixed paraffin-embedded tumour sections. Following
surgery, specimens were fixed in 4% buffered formalin for
at least 24 h, embedded in paraffin, and stored at room
temperature until sectioning. Serial 4-5 μm sections were
cut and adhered onto microscope slides. Paraffin was
removed from the sections using Xylene; the samples were
rehydrated, and processed using the streptavidin-biotin-
peroxidase complex immunohistochemical technique. To
ascertain immunoreactivity, antigen unmasking was per-
formed by microwave treatment with 10 mM citrate
buffer. Incubation with 10% normal goat serum in phos-
phate-buffered saline (PBS) was performed to eliminate
nonspecific staining. After incubating for five minutes in
3% hydrogen peroxide, the slides were then incubated for
30 minutes at room temperature with primary antibody,
VEGF-specific mouse monoclonal IgG (dilution 1:25;
Dako). Detection of primary antibody was achieved with
a secondary antibody detection kit (LSAB+kit, Dako, Den-
mark). Bound antigens were visualized using 3, 3-diami-
nobenzidine as a chromogen. Finally, the sections were
counterstained with Mayer's hematoxylin, dehydrated,
and mounted for analysis. Negative control was per-
formed by incubating with Tris-buffered saline (TBS)
instead of primary antibody. Colon carcinoma, shown to
strongly express VEGF, was used as positive control.
Immunohistochemical analysis
We intended to focus on the positivity in viable tumor tis-
sue and to analyze the "hot spots" of immunoreactivity.Page 2 of 11
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morphologically by hematoxylin and eosin (H&E) stain-
ing, using the serial sections. We compared immunohisto-
chemical stains with preceding H&E slides to ascertain the
exact location of immunoreactivity. Only cancer cells
immunostained for VEGF were measured. The number of
positive cells per 200 × field was assessed. In each slide
three fields were evaluated. Semiquantitative expression
levels of VEGF were determined by assessing both the per-
centage and intensity of stained tumour cells. The percent-
age of positive cells was rated as follows: cases with <1%
positive cells were rated as 0 point, 1-25% positive cells
were rated 1 point; 26-50% positive cells, 2 points; 51-
75% positive cells, 3 points; 76-100% positive cells, 4
points. The staining intensity was rated as follows: 1
point, weak intensity; 2 points, moderate intensity; 3
points, strong intensity. Points for staining intensity and
percentage of positive cells were added, and specimens
were classified into 2 groups according to their overall
score: weak expression 0-2 points; and strong expression,
3-7 points.
Statistical analysis
Descriptive statistics and 95% confidence intervals were
calculated to describe data. Data distribution was ana-
lyzed with the Smirnov-Kolmogorov test. According to the
type of distribution, an appropriate parametric or an
equivalent non-parametric test was used. The cutoff value
for determining VEGF low and high expression score was
performed by the receiver operating characteristic (ROC)
curve analysis [28]. The relationship between VEGF
expression data and gender, age, tumour stage, histology,
stem cell transplantation therapy and survival was esti-
mated by applying the Fisher's exact test [29]. Spearman's
coefficient of rank correlation (rho) was determined to
assess correlation between tumour stage and VEGF score,
as well as VEGF score and survival. Overall survival (OS)
was defined as the interval between the time of estab-
lished diagnosis and patient's death. Univariate analysis
of OS was performed as outlined by Kaplan and Meier
[30]. Statistical significance of differences in survival
between the patients groups with respect to gender, age,
stage, histology, VEGF staining intensity and transplanta-
tion therapy was estimated using the log-rank test. Statis-
tical analysis was performed using GrafPad Prism 5
(GrafPad Software, Inc, San Diego, CA) computer pro-
gram. The Cox proportional hazards model was used for
multivariate analysis to determine independent predictors
of overall survival, and was carried out using MedCalc ver-
sion 10.4 (MedCalc Software bvba, Mariakerke, Belgium)
computer program [31]. Differences were considered sig-
nificant at P < 0.05.
Results
Patient sample classifications
We examined tumour samples of 56 NB patients at dis-
ease onset. Patient characteristics are detailed in Table 1
and Table 2. The median patient follow-up time was 27
months (range, 1.0 to 180.0 months). The overall survival
rate was 62,5%. Regarding age and gender at diagnosis,
the mean age was 35,5 months (range 2 months to 12
Table 1: Patient characteristics
Characteristics No. patients
Total number 56
Gender
Male 35
Female 21
Age
Median 35.5 months
Range 2 months - 12 years
>18 months old 36
≤ 18 months old 20
Histologic subtype
Stroma-rich
Well differentiated 3
Intermixed 10
Focal nodular 3
Stroma-poor
Undifferentiated 30
Differentiating 10
Histology
Favourable 23
Unfavourable 33
Stage
1 3
2 15
3 20
4 17
4s * 1
Treatment
S 3
S/CTH 32
S/CTH/MIBGT 2
S/CTH/RT 2
S/CTH/BMT 14
S/CTH/MIBGT/BMT 2
S/CTH/BMT/RT 1
Survival
Alive 35
Dead 21
Abbreviations: 4s * in infants with small primary tumours and 
metastatic disease involving the skin, liver, limited infiltration of the 
bone marrow, and can spontaneously regress; S, surgery; CTH, 
chemotherapy; MIBGT, metaiodobenzylguanidine therapy; BMT, bone 
marrow transplant; RT, radiotherapyPage 3 of 11
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Patient no./
sex/age (mo) 
at diagnosis
Tumour stage 
at diagnosis
Histologic 
subtype†
Age-linked 
classification‡
VEGF% 
points§
VEGF 
intensity¶
VEGF score® Clinical 
outcome@
1/m/18 2 1a U 1 2 3 S
2/m/36 2 4 U 1 1 2 S
3/m/18 2 1b F 2 2 4 S
4/m/18 2 1a U 2 2 4 S
5/f/37 2 2 F 1 1 2 S
6/m/10 3 1b F 1 1 2 S
7/f/34 2 3 F 1 1 2 S
8/m/121 2 3 F 2 2 4 S
9/m/71 3 3 F 1 2 3 D*
10/m/3 1 1a F 3 2 5 S
11/f/3 4s* 1a U 1 1 2 S
12/f/33 2 1a U 1 2 3 S
13/m/48 3 1a U 4 3 7 S
14/m/53 3 2 F 1 2 3 S
15/m/18 3 1a U 0 0 0 S
16/f/46 2 2 F 2 3 5 S
17/f/2 2 1b F 4 3 7 S
18/m/78 2 2 F 1 1 2 S
19/m/4 3 1b F 2 3 5 S
20/m/2 2 1a F 1 2 3 S
21/m/2 2 1a U 0 0 0 S
22/f/18 3 1b F 1 2 3 S
23/f/14 2 1b F 1 1 2 S
24/m/72 3 2 F 3 3 6 S
25/m/144 4 1a U 2 3 5 D
26/f/24 4 1a U 2 3 5 D
27/m/120 4 1a U 2 3 5 D
28/m/38 3 2 F 2 2 4 D
29/m/120 4 1a U 1 2 3 D
30/m/35 4 1a U 1 2 3 D
31/f/61 4 1a U 2 2 4 D
32/m/97 2 1a U 1 2 3 D
33/m/84 3 1b U 3 2 5 D
34/f/23 4 1b U 2 2 4 D
35/f/42 4 1a U 4 3 7 D
36/f/5 4 1a U 2 3 5 D
37/m/36 3 1a U 3 2 5 D
38/f/48 4 1a U 4 3 7 D
39/m/10 4 1a U 1 2 3 D
40/f/122 2 1a U 1 1 2 S
41/m/38 4 1a U 3 3 6 S
42/f/35 3 2 F 1 4 6 S
43/m/30 1 2 U 1 1 2 S
44/m/3 4 1b F 2 2 4 S
45/f/12 4 1b F 2 3 5 S
46/f/17 3 1a U 2 3 5 S
47/m/18 4 1a U 2 3 5 S
48/m/36 3 2 F 1 1 2 S
49/m/66 4 1b U 1 2 3 S
50/m/12 4 1a F 2 3 5 S
51/m/36 3 2 F 3 2 5 S
52/f/35 4 4 U 1 3 4 D
53/f/54 4 1a U 1 2 3 D
54/m/54 4 4 U 2 3 5 D
55/m/60 3 1a U 3 1 4 D
56/f/56 4 1b U 1 2 3 DPage 4 of 11
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36 patients (64.3%) were >18 months old. 35 patients
(62.5%) were males, and 21 patients (37.5%) females.
Depending of the disease stage, we separated our patients
into two groups: low stage (stage 1 and 2) and high stage
(stage 3 and 4), as well as favourable and unfavourable
histology according to the criteria reported by Shimada, et
al [26,27]. Thirty-seven patients had high stage disease
and eighteen had low stage disease. One patient had 4S
stage disease. Twenty-three patients had favourable and
thirty-thee patients had unfavourable histology. There
was no statistically significant correlation between age (≤
18 months/> 18 months) and disease stage (low/high) (P
= 0.244), or between stage and histology (favourable/
unfavourable) (P = 0.750) as determined by Fisher's exact
test. Also no significant correlation between histology and
age (≤ 18 months/> 18 months) was seen (P = 0.209).
VEGF is expressed in NB samples
According to the criteria proposed by Volms, et al., brown
granules in the cytoplasm of tumour cells were identified
to be VEGF positive [32]. VEGF staining was found in 54
of 56 tumours (96.4%), and only 2 tumours (3.6%) had
negative VEGF immunoreactivity. Most of the specimens
(76, 7%) had 1-50% positive tumour cells, and 76.8% of
specimens had moderate to strong staining intensity. By
assessing both the percentage and intensity of stained
tumour cells, specimens were classified into 2 groups
according to their overall score. By ROC curve analysis,
and cut off value of >2.5 (sensitivity 100%, specificity
56.25%), tumours were distinguished with high (3-7) and
low (0-2) VEGF expression scores. Low VEGF expression
scores were found in 12 NB (21.4%) and high expression
score in 44 NB (78.6%) (Table 3). Figure 1 is showing
VEGF immunohistochemical staining in different NB
pathohistological sections.
Correlation of VEGF expression with clinicopathological 
characteristics and survival
VEGF expression and clinicopathological characteristics
are detailed in Table 4. Fisher's exact test was performed.
We did not observe significant correlation between VEGF
expression (high/low) and gender (P = 0.7477), age >18
months/≤ 18 months old (P = 0.2701), or histology
(favourable/unfavourable) (P = 0.27). Also, there was no
significant difference in VEGF expression between the
transplant and non-transplant patients (P = 0.7378).
There was significant association between advanced dis-
ease stage and high VEGF expression as determined by
Fisher exact test (P = 0.0014), and significant correlation
between high VEGF expression score and high tumour
stage as determined by Spearman's coefficient of rank,
(rho = 0.453, P = 0.0005).
The VEGF expression score was significantly higher in the
group of non-survival patients compared to the group of
patients that survived more than 5 years, as determined by
Mann Whitney test (P < 0.0001). Also, significant correla-
tion between VEGF expression and survival was deter-
mined by Spearman's coefficient of rank (rho = -0.472, P
= 0.0002). All patients with low VEGF expression score
survived.
Interestingly, in the group of patients ≤ 18 months old we
did not observe any correlation between VEGF expression
and tumour stage (Spearman's coefficient of rank rho =
0.17, P = 0.46), opposite to the patients > 18 months old
(rho = 0.635, P < 0.0001). In the same group of patients
(≤ 18 months old), we also did not observe any correla-
tion between VEGF expression score and survival (Spear-
man's coefficient of rank rho = 0.19, P = 0.42; Fisher's
exact test P = 1.0), contrary to the group of patients > 18
months old (Spearman's coefficient of rank rho = 0.49, P
= 0.0023; Fisher's exact test P = 0.0076), (Figure 2).
Univariate survival analysis
Log-rank test was performed. There were significant differ-
ences in survival rates in the groups of patients with ≤ and
> 18 months old (P = 0.0069; Table 5). Patients > 18
months old had lower survival rate than patients ≤ 18
months old. Patients with advanced stage tumours (Stage
3, 4), had lower survival rate when compared to patients
with low stage tumours (P = 0.0006; Table 5). There were
significant differences in survival rates in the groups of
patients with favourable and unfavourable histology (P <
0.0001; Table 5). Patients with high VEGF expression had
short median OS (30 months). Survival curve of the VEGF
 Tumour staging at diagnosis according to INSS25;
† Shimada histopathologic classification26 1a: Stroma poor, undifferentiated; 1b: Stroma poor, differentiating; 2: Stroma rich, intermixed; 3: Stroma 
rich, well differentiated; 4: Stroma rich, focal nodular
‡ Prognostic groups according to the age-linked classification of Shimada26 F: favourable; U: unfavourable;
§VEGF % (percentage of positive VEGF cells) 0 point: <1% positive cells, 1 point: 1-25% positive cells; 2 points: 26-50% positive cells; 3 points: 51-
75% positive cells; 4 points: 76-100% positive cells
¶VEGF intensity (staining intensity) 1: weak intensity; 2: moderate intensity; 3: strong intensity
® VEGF score: points for staining intensity and percentage of positive cells were added
@ S: surviving, D: dead, D*: one patient died in relapse of tumour 5,5 yr after diagnosis
4S* in a infant with small primary tumour and metastatic disease involving the skin, liver, limited infiltration of the bone marrow
Table 2: Patient characteristics (Continued)Page 5 of 11
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:143 http://www.jeccr.com/content/28/1/143low expression group was significantly higher, and OS
longer, compared to the VEGF high expression group (P =
0.0053; Figure 3, Table 5). Survival was not correlated
with sex (P = 0.45; Table 5).
High risk patients
Patients with high disease stage (Stage 3, 4) and high
VEGF expression score (score 3-7) had short median OS
(24 months). These patients had significantly lower sur-
vival rate than all other patients (p < 0.0001; Table 5, Fig-
ure 4). The non-transplant patients with high stage disease
and high VEGF expression score (high risk patients), had
the shortest median OS (13 months) and significantly
lower survival rate when compared to all other (low risk)
non transplant patients (p < 0.0001). Among the high-risk
patients (high stage and high VEGF expression), those
patients who had bone marrow transplants had signifi-
cantly better survival rate (undefined median OS) when
compared to non-transplant patients (median OS 13
months) (p = 0.0237).
Tumour stage and VEGF expression, as one combined 
variable - the significant mortality predictor by 
multivariate analysis
The full Cox proportional-hazards regression model con-
taining all predictors was statistically significant (P <
0.001), indicating that this model was able to distinguish
between survival and non-survival. As shown in Table 6,
three predictor variables significantly affected the model,
unfavourable histology, high disease stage, and transplan-
tation. Although we did not demonstrate the role of VEGF
as an independent prognostic factor by multivariate anal-
ysis, the combination of high tumour stage and high
VEGF expression as one complex predictor variable,
became the strongest mortality predictor by Cox propor-
tional-hazards regression model (OR = 26.1695, 95% CI
= 2.9741 to 230.2670, P = 0.0034; Table 7). These results
showed that prognostic prediction might be improved by
taking into account both VEGF expression and disease
stage.
Immunohistochemical staining for VEGF in different NB pathohistological sectionsFigure 1
Immunohistochemical staining for VEGF in different 
NB pathohistological sections. Low VEGF expression 
score with low grade intensity and 1-25% tumour cell positiv-
ity (A); High VEGF expression score with high grade inten-
sity and 25-50% tumour cell positivity (B); High VEGF 
expression score with moderate grade intensity and 75%-
100% tumour cell positivity (C). Objective = 40×.
Table 3: Immunoreactivity of VEGF, and the number of patients
Category Number of patients (%) alive/dead
Percentage of positive
tumour cells (P)
<1% 2 (3.6%) 2/0
1-25% 25 (44.6%) 17/8
26-50% 18 (32.1%) 10/8
51-75% 7 (12.5%) 4/3
76-100% 4 (7.1%) 2/2
Staining intensity (I)
Negative 2 (3.6%) 2/0
Weak 11 (19.6%) 10/1
Moderate 24 (42.9%) 12/12
Strong 19 (33.9%) 11/8
Expression score (P+I)
Low (0-2) 12 (21.4%) 12/0
High (3-7) 44 (78.6%) 23/21Page 6 of 11
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So far, in some adult solid tumours semi-quantitative
VEGF expression has been successfully evaluated by
immunohistochemistry, and VEGF has been reported to
be an independent prognostic factor [11-15]. We per-
formed similar investigation in the cohort of patients with
neuroblastoma which is the most frequent extra cranial
solid malignancy in children and has a great mortality
rate. In order to evaluate the prognostic significance of
VEGF expression in NB patients, and estimate its diagnos-
tic usefulness in a routine clinical practice, we have
attempted to establish semi-quantitative VEGF score. As
we intended to focus on positivity in viable tumour tissue,
the most reliable method was immunohistochemistry. To
our knowledge, this is the first time that VEGF immuno-
histochemistry score has been evaluated in NB patients.
We analyzed "hot spots" of immunoreactivity which
could be easily missed by other techniques.
In our cohort VEGF positive immunostaining was found
in 96.4% of all NB tumour specimens tested, with most
samples having moderate to strong staining intensity
(78.6%). Despite some differences in scoring systems
described in different studies, the frequency of VEGF pos-
itive tumours in this study was higher than in adult can-
cers [11,13-15]. It can be explained by NB-specific biology
and significant tumour tissue hypoxia [8,33,34].
No correlation between VEGF expression and gender, age,
or histology was found. However, there was significant
correlation between high stage and high VEGF expression,
and between high VEGF expression and short survival.
Contrary to the patients with high VEGF expression, all
patients with low VEGF expression survived.
These results support the hypothesis of a dual function for
VEGF in autocrine tumour growth. In addition to its
Table 4: VEGF expression and other clinicopathologic factors
Characteristics VEGF score
Low High
No. patients
Total number 12 44
Gender
Male 7 28
Female 5 16
Age
>18 months old 4 32
≤ 18 months old 8 12
Histologic subtype
Stroma-rich
Well differentiated 1 2
Intermixed 3 7
Focal nodular 1 2
Stroma-poor
Undifferentiated 6 24
Differentiating 1 9
Histology
Favourable 5 18
Unfavourable 7 26
Stage
1 1 2
2 7 8
3 3 17
4 0 17
4s 1 0
Transplant
No 9 30
Yes 3 14
Survival
Alive 12 23
Dead 0 21
The impact of VEGF on survival in different age groupsFigure 2
The impact of VEGF on survival in different age 
groups. Expression of VEGF has impact on survival in the 
patients > 18 months old (A). VEGF expression is not statis-
tically significant for survival in the group of patients ≤ 18 
months old (B).Page 7 of 11
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directly, and could be an autocrine growth factor [35]. In
addition to stimulating angiogenesis in tumour growth,
VEGF also mediates neuroprotection promoting neurob-
lastoma cellular survival by increasing Bcl-2 and pro-cas-
pase 3 expressions [36].
Additional trials also confirm the correlation between
VEGF expression and the grade of NB [5,35,37,38]. VEGF
levels in the sera of metastatic NB patients and other pae-
diatric solid tumour patients are much higher than in
non-metastatic patients [39]. Other authors did not find
correlation between VEGF expression and disease stage,
but they found association between high VEGF expression
and unfavourable histology [19]. Perhaps, the differences
between the results were caused by small patient groups
and different methods of VEGF evaluation. Larger multi-
centric studies are needed to obtain more reproducible
results. Also, new experimental models to study the ang-
iogenic and invasive potential of NB tumours cells are still
needed in order to further investigate human tumour pro-
gression and anti-angiogenic molecule screening [40,41].
As we mentioned, we found significant correlation
between high stage and high VEGF expression, and strong
correlation between high VEGF expression and short sur-
vival in the cohort of our NB patient, except in the patients
with age ≤ 18 months old. Patients younger than 18
months have a good prognosis, and spontaneous tumour
maturation/regression can happen due to favourable
autocrine and paracrine interactions among tumour cells.
We suppose that in these tumours the effects of VEGF
could be diminished by stimulators of tumour matura-
tion, but further prospective designed neuroblastoma
angiogenesis/anti-angiogenesis studies are needed to
VEGF and survival by Kaplan-Meier analysisFigure 3
VEGF and survival by Kaplan-Meier analysis. Expres-
sion of VEGF is a significant prognostic factor. Kaplan-Meier 
analysis of overall survival for all NB patients according to 
high and low VEGF expression (P = 0.0052).
Table 5: Overall survival rates and univariate analysis of patients with NB according to clinicopathologic factors
Variable Number of patients Overall survival rates Log-rank Test
Gender
boys 35 68.6% P = 0.4497
girls 21 57.1%
Age
≤ 18 months 20 90% P = 0.0069
> 18 months 36 50%
Stage
high 37 50.0% P = 0.0006
low 18 94.4%
Histology
favourable 23 95.7% P < 0.0001
unfavourable 33 42.4%
VEGF expression
high 44 54.5% P = 0.0053
low 12 100.0%
Risk group
high* 34 44.1% P < 0.0001
low** 22 95.5%
Abbreviations:*high VEGF expression (score3-7) together with high disease stage (Stage III, IV);
**all othersPage 8 of 11
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epithelium-derived factor (PEDF) which is inhibitor of
angiogenesis and inducer of neural differentiation [42]. In
the study of Crawford SE, et al. (2001), "undifferentiated
neuroblastoma tumour cell secretions were angiogenic
primarily due to vascular endothelial growth factor, and
secretions of Schwann cells were anti-angiogenic due to
PEDF. In addition, PEDF was the major factor responsible
for Schwann cell's ability to induce tumour cell differenti-
ation in vitro and recombinant PEDF had the same effect
in vitro and in vivo. Thus PEDF may serve as a multifunc-
tional antitumor agent in neuroblastomas" [42].
Survival rates of our NB patients were analyzed according
to gender, age, stage, histology, and VEGF expression. In
accordance with previous reports (1), age > 18 months
was a significant prognostic factor. By univariate analysis,
tumour stage, favourable/unfavourable histology and
VEGF immunoreactivity were also found to be significant
prognostic factors for overall survival. By combining
VEGF expression and disease stage the prognostic value
for survival was even more improved. Patients with high
tumour stage and high VEGF expression were high-risk,
with short median of overall survival (OS) (24 months).
Among this group, there were significant differences in OS
between transplant (undefined median OS), and non-
transplant patients (13 months median OS). Multimodal
therapy with hematopoietic stem cell transplantation sig-
nificantly improved survival of these high risk patients.
Perhaps survival rates could be further improved by add-
ing bevacizumab in their therapy because in addition to
its antiangiogenic and proapoptotic properties, bevacizu-
mab can transiently "normalize" the abnormal structure
and function of tumour vasculature to make it more effi-
cient for oxygen and drug delivery [43]. If bevacizumab
treatment suppresses NB progression in the setting of
minimal residual disease, it would likely be a good ther-
apy option post stem cell transplantation for high VEGF
expression, high risk patients [44].
In multivariate analysis by the Cox regression model, Shi-
mada histopathology age-linked classification, tumour
stage and hematopoietic stem cell transplantation had sig-
nificance as independent prognostic factors for overall
survival. Although we did not demonstrate the role of
VEGF expression score as an independent prognostic fac-
tor by multivariate analysis, the combination of high
tumour stage and high VEGF expression as one complex
predictor variable was the strongest mortality predictor by
Cox proportional-hazards regression model.
As tumour angiogenesis correlates with metastatic disease,
N-myc amplification, and poor outcome in human neu-
roblastoma, and some studies suggest that N-myc may
function in part by promoting angiogenesis via VEGF, it
would be important to compare N-myc amplification with
VEGF expression in the clinical trials [3,41]. Due to our
failure to obtain DNA of sufficient quality when we tried
to prepare paraffin-embedded material for molecular
biology study, we were not able to correlate N-myc ampli-
fication level and VEGF expression. Nevertheless, our
results indicated that VEGF expression should be consid-
ered in the diagnostic workup of children with neuroblas-
toma, especially in those older than 18 months and with
advanced disease stage.
Conclusion
This study suggests that VEGF, a critical regulator of
tumour angiogenesis, might serve as an important neu-
roblastoma prognostic biological marker in a routine clin-
ical practice. It can be used to identify neuroblastoma
high risk patients in combination with tumour stage and
High risk group and survival by Kaplan-Meier analysisFi ure 4
High risk group and survival by Kaplan-Meier analy-
sis. High risk group has short overall survival (OS) (24.00 
months). Kaplan-Meier analysis of OS according to risk 
groups* for NB patients (P < 0.0001). Abbreviation: risk 
groups* = high risk group: patients with high disease stage 
(stage III, IV) and high VEGF expression score (3-7); low risk 
group: all other patients.
Table 6: Cox proportional-hazards regression model* for NB 
patients overall survival
Covariate P OR** 95% CI***of OR
High stage 0.0238 11.3891 1.3949 to 92.9926
VEGF expression score 0.3831 1.1790 0.8159 to 1.7038
Unfavourable histology 0.0073 16.4610 2.1432 to 126.4302
Age older than 18 months 0.1988 3.0418 0.5624 to 16.4532
Without transplantation 0.0295 3.2280 1.1298 to 9.2227
*Overall model fit χ2 = 42.105 P < 0.0001
Abbreviations: **Odds ratio; *** Confidence intervalPage 9 of 11
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would be useful in determining the necessity for stem cell
transplantation, determining follow-up strategies and
anti-angiogenic therapy trials.
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